MicroPort Scientific Corporation

2025 Interim Results

September 2025

MicroPort 微创

Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Contents

1H25 Financial Results



Revenue

$ 548M

(2.2)% YoY

Net Loss

$ 36M

Narrowed 66% YoY

Non-GAAP

Net Loss

Breakeven

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

1H25 Portfolio Highlights

	Bottom-line Improvement	Going-abroad Momentum
	EBITDA $128M ▲116%YOY	**Going-abroad Revenue** ~$60M ▲57.3%YOY
Cardiovascular	Net profit ▲64.4%YOY	Increasing sales contribution of active device
Orthopedics	Net loss narrowed 58%YOY EBITDA ▲28.5%YOY	FDA approval for domestic total knee system
CRM	EBITDA breakeven	*Not Applicable*
Endovascular	Net profit $43mn	Overseas rev. ▲95%
Neurovascular	Adjusted net profit ratio 39%	Overseas rev. ▲67%
Structural Heart	Net loss at $0.4mn, narrowed 96.2%YOY	Overseas rev. ▲235%
Surgical Robot	Net loss narrowed 58.9%YOY	Overseas rev. ▲189%

Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Positioning for Next Chapter of Value Creation

Partnership with SIIC Capital

- Welcoming a new **strategic shareholder**.
- **Facilitate** the development of MicroPort®'s core businesses by leveraging SIIC Capital's state-owned enterprise background and extensive industrial resources.
- **In pursuit** of higher standards of corporate governance.
- **Supports** MicroPort®'s continued innovation, high-quality development as well as scale and capacity upgrade.

Proposed Restructuring of CardioFlow and CRM

- **Complementing** product portfolio with diversified products and product pipelines as a cardiology platform.
- **Sharing** of international marketing and sales resources.
- **Expansion** of the business scale and growth potential, enhancing the revenue, profitability and cashflow of both businesses.
- **Enhancing** the capital market's recognition of the underlying value and growth potential of both businesses.

Unlock Growth Potential

Opportunities beyond the Sum of Its Parts

We Are Proud to Receive Another World-class Recognition

New England Journal of Medicine Published TARGET-FIRST



- 1-Month DAPT with Firehawk® Stents Lowers Bleeding without Increasing Ischemic Events.
  - Shortening dual-antiplatelet therapy (DAPT) duration from 1 year to 1 month
  - Maintained ischemic protection and reduced bleeding

The World's Only Target Eluting Stent Supported by 1 Month of DAPT



- Advances patient outcomes and generates clear health-economic value.
  - Lowering costs
  - Mitigating risks
  - Enhancing quality of life across the care continuum

The honour and privilege reflects the unique value of the Firehawk® Stents and significantly enhance MicroPort®'s academic influence worldwide

Our Unique Infrastructure

1H25 Going-abroad Updates

~$ 60mn
Sales Revenue

▲57.3%
YOY Growth

1H25 Innovation Updates

4
NMPA Green Paths

20
NMPA Approvals
(Class III initial)

232
Overseas Approvals

GloMatrix Platform

Cardiovascular	Orthopedics	CRM	Endovascular	Neurovascular	Structural Heart	Surgical Robots
Implants	Reconstructive Joints	Low Voltage	Aortic	AIS	TAVI	Percutaneous
Access	Spine	High Voltage	Peripheral	CAS	TMV	Laparoscopic
Active	Truama	PGM/RMS	Oncological	Access	LAA	Orthopedics
Imaging				Hemorrhagic Stroke	TTV	Panvascular
Intervention without Implants						Natural Orifice

Domestic

- TomaHawk® Integrated Coronary Intravascular Lithotripsy System
- Firelimus® Coronary Rapamycin-Eluting Balloon
- 3.0T MRI TEN™ Pacemaker Family
- Cratos® Branched Aortic Stent Graft and Delivery System
- Tipspear® Transjugular Intrahepatic Puncture Kit
- NeuroHawk Medibox™ Intracranial Stent Retriever and Accessories
- Numen® Nest Detachable Coil
- Toumai® Telesurgery Robotic System
- Toumai® Single-port Endoscopic Surgical Robot

Overseas

- Evolution® MPX™ Total Knee System — FDA
- NEXUS® Hip Stem — FDA
- Minos® Abdominal Aortic Stent-Graft and Delivery System — CE
- Hercules® Low Profile Thoracic Stent Graft and Delivery System
- Numen™ Coil Embolization System — CE
- NeuroHawk™ Thrombectomy Device — CE
- AnchorMan® Left Atrial Appendage Closure System — CE
- Alwide® Plus Balloon Catheter — CE

100+
Countries/ Regions

20,000+
Medical Institutions Worldwide

Note: revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies.

Contents

Cardiovascular Business: Net Profit Increased by 64.4%

China

- **Maintaining leading position while actively integrating product portfolio**
  - **1H25 revenue remained stable**, among which the DES products maintained **No.1 market share,** balloon revenue **▲38.3%**YOY**,** accessories revenue **▲20.7%**YOY**.**
  - Embarks the complete coronary solution strategy and **actively accelerates the market adoption for new products.**
- **Incremental sales contribution of new products**
- **NMPA approvals:**
  - **TomaHawk®** Shockwave Intravascular Lithotripsy (IVL) System and Shockwave Catheter
  - **Firelimus®** Coronary Rapamycin Drug-Coated Balloon
  - **Firehawk® Elite** Stent (Iteration for Firehawk®**)**
- **Progress in innovative pipeline**
  - **Coronary Graft Stent System** completed patient enrollment pre-market clinical trail.
  - **Coronary Sinus Balloon Counterpulsation System** starts patient enrollment for pre-market clinical trail.

Non-China

- **Revenue growth experiencing short term disruption**
  - **1H25 revenue (10.2)%**YOY due to conflict in Middle East, fluctuations of healthcare system in certain area of Asia-Pacific, as well as the channel adjustment in certain areas.
  - EMEA **▲8.0%**YOY, Asia-Pacific (excluding China) **(39.8)%**YOY and Latin America **(12.1)%**YOY**.**
- **Expanded overseas coverage while structurally optimizing our sales channel**
- **Worldwide academic influence**
  - Clinical study of **FireRaptor® Rotational Atherectomy System released at the EuroPCR 2025** held at the Paris Conference Center in France, indicating demonstrated excellent safety and efficacy in treatment of moderately and severely calcified lesions in coronary arteries.





Redefine Our Line of Sight with Most Complete Portfolio Worldwide

2025 YTD Approval

Implant Device	NMPA approved **Firebird2® Rapamycin-Eluting Coronary Stent System**	NMPA approved **Firehawk® Rapamycin Target Eluting Coronary Stent System**	NMPA approved **Firehawk® Elite Rapamycin Target Eluting Coronary Stent System**
Intervention without Implantation	NMPA approved **Firesorb® Bioresorbable Rapamycin Eluting Coronary Scaffold System**	NMPA approved **Firelimus®** Coronary Rapamycin-Eluting Balloon Dilatation Catheter	
Access Device	NMPA approved **Firefighter™ PTCA Balloon Catheter**	NMPA approved **FireFalcon® Coronary Scoring Balloon Catheter**	NMPA approved **Bilumos® Dual-lumen Catheter**	NMPA approved **Firefighter™ Pro mini** Coronary Balloon Dilatation Catheter
Active Device	NMPA approved **TomaHawk®** Shockwave Intravascular Lithotripsy System	NMPA approved **FireRaptor®** Rotational Atherectomy System	NMPA GreenPath Upcoming NMPA Approval **I-percker** intravascular piezoelectric guidewire system
Imaging Diagnostic Devices	NMPA approved **Argusclarity® Insight-100h Optical Coherence Tomography System**	NMPA approved **Soul-Man™ Digital Subtracting Angiography System**	NMPA approved **Decypher® Intravascular Ultrasound Imaging System**

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

Orthopedics Business: Net Loss Narrowed by 58% with Positive FCF

China

- **1H25 revenue (2.8)%**YOY, due to delayed execution of 2nd round VBP and lags in the transition between old and new growth drivers due to short-term product mix adjustments.
- Seizing the transition window of 2nd round VBP execution to actively gaining market access for our domestic products, paving way for future growth.
- Sales revenue of **domestic TKA and domestic THA** increased **▲171%**YOY and **▲28%**YOY**,** respectively.
- **GPM improved** due to growing contribution of domestic products.
- **Breakeven achieved** in 1H25 due to continuous efforts in cost reduction and efficiency gains.
- **NMPA approval** obtained for Evolution® MPX™ Internal Axis Total Knee Joint System, complementing our existing simple primary replacement solutions and ongoing revision solutions under development.
- **FDA approval** obtained for domestic TKA system, providing cost-effective choices with premium quality for patients worldwide.

Non-China

- **1H25 revenue (3.8)%**YOY**,** due to conflict in Middle East and volatility in supply chain impacted by global tariff disruption. US recovering from lingering impact from historical backorders, while other regions remained revenue growth.
- Growing recognition of robotic-assisted procedures worldwide and the successful execution of our total solution of Medial Pivot Knee System & SkyWalker™ Orthopedics Surgical Robot.
- **1H25 net loss narrowed by 30.4%**YOY.
- Continuous efforts in enhancement of the flexibility and resilience of global supply chain by strengthening inter-segment collaboration.
- **FDA approval** obtained for Nexus® Hip Stem, engagement of more KOLs and distributors is expected through the upcoming new product launches.

Revenue

USD: million



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

CRM Business: EBITDA Breakeven

China

- **1H25 revenue (1.0)%**YOY due to delayed VBP execution.
- **Revenue contribution from ICD products** came in 1H25 for the first time.
- **Continuous efforts in developing hospital penetration of our substantially enriched product pipeline** incl. imported 1.5T/3T Full-body MRI-compatible **ENO™** Series Pacemaker**,** Active Fixation Pacing Leads **Vega™**, the first domestically made ICD **Platinium™**, MRI-compatible Passive Fixed Pacing Lead **BonaFire™**, 3.0T Whole-body MRI-compatible **TEN™** Series Pacemaker.
- Progress made in market access with ENO™ Series Pacemaker, TEN™ Series Pacemaker, Vega™ Leads completed listed on 24, 20, 24 provincial procurement platforms, respectively.
- **NMPA approval**: 3.0T Whole-body MRI-compatible TEN™ Series Pacemaker, which is the China's **first and only** domestically produced pacemaker series achieving full-body 3.0T MRI compatibility.

Non-China

- **1H25 revenue (1.5)%**YOY with sales revenue of ICD ▲**1.2%**YOY, CRT-D ▲**11.2%**YOY while pacemakers decreased due to the increasing penetration of leadless and LBBAP technologies.
- **First step in the exploration of LBBAP solutions** : CE mark-MDR approval for ALIZEA™ family pacemakers featuring LBBAP.
- **Clinical affairs milestones:**
  - **POLARIS Study:** Surpassed early enrollment goals for the FLEXIGO™ Catheter Guide, with Phase 2 slated for late 2025.
  - **PIANO Study:** Exceeded 500 patient enrollments in its ICD cohort, Japan-specific SonR® CRT-D sub-study launched in May.

Key approvals:

- **CE mark** for the world's first MR Conditional Mixed Pacing System with ALIZEA™ range
- **FDA clearance** for FLEXIGO™ Delivery System

- **Strategic Partnership** with Andhra Pradesh MedTech Zone (AMTZ) in India and leveraging MicroPort®'s GloMatrix Platform to scale up product access.
- **Our Legacy in innovation:**the 30th anniversary of the world's first dual-chamber ICD implantation, DEFENDER™.

Revenue

USD: million



Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

Endovascular Business



China

- **1H25 revenue (17.6)%**YOY, due to the introduction of industry policies in 2H24, which led to price reduction of key products.
- Growing contribution from **peripheral products** with sales revenue **▲52.8%**YOY.
- **Strong clinical demand** for star products incl. Castor®, Talos®, Minos® and Fontus®, with their implant volume increased substantially.
- **Continuous enrichment in product portfolio in Endo, peripheral & tumor intervention with further development:**
  - **NMPA approvals**: Cratos® Branched Aortic Stent-graft System, Tipspear® Transjugular Liver Access Set
  - **Green Path:** Hector®, the 1st triple-branch stent, further extending aortic endoluminal treatment to the entire aortic arch, addressing the urgent clinical needs.

Non-China

- **1H25 revenue ▲95.2%**YOY, the proportion of overseas revenue increased from 8.8% in 1H24 to 17.3% in 1H25.
- **Continuous global penetration**: presence in **45** countries and regions to date, with **5** countries newly developed.
- **Market expansion of key products**: Castor® entered into **27** countries, Minos® entered into **27** countries, Hercules® Low Profile entered into **27** countries, Cratos® entered into **9** countries to date.
- **Swiftly advancing overseas sales channel**: its innovative products covered **45** markets accumulatively, across EU, Latin America and Southeast Asia.
- **Significant progress for NMPA products going abroad:**
  - 5 CE marks to date
  - Hector® received the EU Customized Certificate.

	Product	Pre-clinical	Clinical	Registration
Aortic Intervention	L-REBOA® Aortic Occlusion Balloon Catheter			• NMPA approved
	Cratos® Branched Aortic Stent-Graft System			✓ Obtained **NMPA approval** • EU Customized Certificate
	Aegis® II Abdominal Aortic Stent-Graft System		• Conducting pre-market clinical trial	
	Hector® Multi-branched Aortic Stent-Graft System			✓ **Awarded the EU Customized Certificate**
	Aortic Tear Flow-Restriction Stent		• Conducting FIM clinical trial	
Peripheral Venous Intervention	Vflower® Venous Stent System			• NMPA approved
	Vewatch® Vena Cava Filter			• NMPA approved
	Vepack® Filter Retriever			• NMPA approved
	Fishhawk® Mechanical Thrombectomy Catheter		• Under NMPA review	
Peripheral Arterial Intervention	ReeAmber® Balloon Dilation Catheter			• NMPA approved
	HawkNest® Fibered Embolization Coil			• NMPA approved
	SunRiver™ Below-the-knee Drug-coated Balloon Catheter		• Conducting pre-market clinical trial	
Oncological Intervention	HepaFlow® TIPS Stent Graft System		• Under NMPA review	
	Tipspear® Transjugular Liver Access Set			✓ Obtained **NMPA approval**
	FinderSphere® / FluentSphere® Polyvinyl Alcohol Embolization Microsphere		• Under NMPA review	

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

Neurovascular Business



China

- **1H25 revenue (11.6)%**YOY due to price reduction of core products under VBP announced in 2H24, while coil products maintained rapid revenue growth.
- Maintaining **No.1 market share** in neurovascular area among domestic brands[2].
- **Increasing coverage of high-quality hospitals**: ~**150** hospitals developed, with a total coverage of ~**3,600** hospitals, accumulated support for approximately **250,000** neuro-interventional surgeries.
- Increasing market demand driven by VBP price cut with implant volume of core products increased rapidly.
- **4 NMPA approvals**: incl. NUMEN® Nest Detachable Coil, Neurohawk® Medibox™ Intracranial Stent Retriever, Sheathru™ Delivery Catheter, Cerelmon™ Filter Extension Tube

Non-China

- **1H25 revenue ▲67.4%**YOY, the proportion of overseas revenue increased from 6.9% in 1H24 to **12.3%** in 1H25.
- Revenue of EMEA **▲125%**YOY, Asia Pacific **▲48%**YOY, North America **▲146%**YOY
- Breakeven achieved and profits grew rapidly in 1H25
- **Significant progress for NMPA products going abroad:**
  - **8** products commercialized in **34** overseas countries in total with 11 newly developed
  - Covering 9 of the top 10 countries worldwide in terms of the number of neuro-interventional procedures
  - **9** products obtained approval in 1H25, **CE Mark** obtained for NeuroHawk® Thrombectomy Device

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	Tubridge® Flow-diverting Stent for small and medium-sized aneurysm			✓ Obtained NMPA approval
	Numen® Silk 3D Electronically Detachable Coil			• NMPA approved
	NuFairy™ Absorbable Coil Embolization System		• Conducting clinical trial	
	Rebridge® Intracranial Visualized Stent		• Conducting clinical trial	
CAS	NUMEN® Nest Detachable Coil			✓ Obtained NMPA approval
	Bridge® MAX Vertebral Artery DES			✓ Submitted for NMPA review
	Safecer™ Embolic Protection Device			• NMPA approved
	Pathfinder™ Carotid Artery Dilatation Catheter			• NMPA approved
	Intracranial Drug-Coated Balloon Catheter System		• Conducting clinical trial	
AIS & Access	NeuroHawk® Thrombectomy Device			• NMPA approved
	Neurohawk® Medibox™ Intracranial Stent Retriever			✓ Obtained NMPA approval
	Sheathru™ Delivery Catheter			✓ Obtained NMPA approval
	Cerelmon™ filter extension tube			✓ Obtained NMPA approval

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. in terms of sales revenue 3. refers to initial registration/approvals of 29 August 2025.

Structural Heart Diseases Business: Net Loss Narrowed 96%



China

- **1H25 revenue (6.1)%**YOY, and the first revenue contribution VitaFlow Liberty® Flex came in, which is the 3rd generation TAVI approved at the end of 2024.
- **Steady market penetration progress**
  - **2,146** implantations of TAVI products
  - **400+** implantation of LAAC
- **Increased hospital coverage**:
  - TAVI explored access to **30+** new hospitals with **~680** hospitals coverage in total.
  - LAAC explored access to **30+** new hospitals with **~90** hospitals coverage in total.

Non-China

- **1H25 revenue ▲235.3%**YOY, core products accelerated the development of international markets.
- **~250 implantations of TAVI products,** representing **▲200%+**YOY.
- **Expanded global presence:**
  - TAVI products have been introduced into **~140** core hospitals in **20+** countries and regions overseas to date.
  - LAAC obtained efficient
- **2 CE Marks obtained:**
  - AnchorMan® LAAC System, China's **first and only** LAAC system with both CE-MDR and NMPA approvals
  - Alwide® Plus Balloon Catheter, the 4th CE Marked product of structural heart business

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow®	• NMPA approved • Registered in Argentina and Thailand		
TAVI	VitaFlow Liberty®	• NMPA approved		
TAVI	VitaFlow Liberty® Flex	• NMPA approved		
TAVI	VitaFlow Liberty® Pro	• Design stage		
TAVI	VitaFlow® AR	• Design stage		
Access-ories	Alwide® Plus Balloon Catheter	• NMPA approved ✓ **Obtained CE Mark**		
Access-ories	AccuSniper™ Double Layer Balloon Catheter	• NMPA approved		
TMV	VitaFlow® SELFValve™	• FIM study		
TMV	AltaValve™ - Replacement product *(Partnership with 4C Medical)*	• Dual FDA Breakthrough Device • Global pivotal study in progress		
TTV	VitaFlow® Triumph™	• Design Stage		
TTV	Replacement product *(Partnership with 4C Medical)*	• Design Stage		
LAA products	AnchorMan® Left Atrial Appendage Closure System	• NMPA approved ✓ **Obtained CE Mark**		
LAA products	AnchorMan® Left Atrial Appendage Access System	• NMPA approved		
LAA products	AnchorMan® Pro Left Atrial Appendage Closure System	• Design Stage		
LAA products	AnchorMan® Pro Left Atrial Appendage Access System	• Design Stage		

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

Surgical Robot Business: Net Loss Narrowed 59% with FCF Improved 43%



No. 1 Among Domestic Brands

- **1H25 revenue ▲77%**YOY, overseas revenue **▲189%**YOY
- **Toumai®:**
  - Accumulated **~90** units of orders received globally.
    (Including accumulatively **50+** orders from overseas market)
  - **22** units of new installation in 1H25, giving a total of **60+** units installation base to date.
  - **>10%** of revenue from sales of instruments & accessories.
- **SkyWalker™:**
  - Accumulated **~60** units of orders received globally.
  - **10+** units of new orders received in 1H25, mainly from developed countries.
  - **8** units of new installation in 1H25.
- **R-ONE®:**
  - **5** units of commercialized installation in the top public hospitals in Shanghai.

Global Installation Base
(Commercialized, by Jun 30, 2025)

Toumai Hope of Life		SkyWalker	
China:	36	China:	8
Overseas:	27	Overseas:	27

The World's 1st & ONLY – TOUMAI® Remote

- **1st and only** approved remote surgical robot, leading the surgical robot industry into the **remote era**.
- The **world's 1st FDA IDE-approved** clinical remote tele-surgery trial conducted.
- **~500** remote surgeries completed by Toumai® to date, created **50+** national/ world records.
- **1st and only** intercontinental remote surgery network, covering **103** countries and regions, **229** cities, and **465** data centers.

Laparoscopic | Orthopedic | Natural Orifice | Panvascular | Percutaneous

Product	Pre-clinical	Clinical	Registration
Toumai® Laparoscopic Surgical Robot			• NMPA approved • 30+ registration approvals globally
Toumai® Remote Laparoscopic Surgical Robot			✓ Obtained **NMPA approval**
Toumai® Single-port Laparoscopic Surgical Robot			✓ Obtained **NMPA approval**
DFVision® 3D Electronic Laparoscope			• NMPA approved
SkyWalker™ Orthopedic Surgical Robot			• NMPA approved • 10 registration approvals globally ✓ **THA obtained CE Mark**
Trans-bronchial Surgical Robot			✓ **Submitted for NMPA review**
R-ONE® Panvascular Surgical Robot			• NMPA approved
iSR'obot® Mona Lisa Robotic Transperineal Prostate Biopsy System			• NMPA approved

Product admitted to NMPA Green Path

Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US$ against functional currencies. 2. refers to initial registration/approvals of 29 August 2025.

Contents

Income Statement Highlights

Revenue

USD: million



Gross Margin



Operating Expenses

USD: million



Operating Expenses Ratio%



Income Statement Highlights (Continued)

Net Loss

USD: million



Non-HKFRS Adjusted Net Loss

USD: million



EBITDA

USD: million



Cashflow Highlights

Operating Cashflow

USD: million



Capital Expenditure

USD: million



Adjusted Cash and Cash Equivalent

USD: million



Note: Balance includes cash and cash equivalents, pledged deposits and time deposits, and financial assets measured at FVPL

Contents

Product Pipeline

Cardio-vascular	**Piezoelectric Guidewire Equipment**	**Piezoelectric Guidewire accessories** 	**Coronary Stent Graft System**	**Firehawk®** FDA 	**Coronary Sinus Balloon Counterpulsation System**	**Coronary Laser Ablation System**	**Guide Extension Catheter**
Orthopedics	**New Primary Knee System**	**Nexus Hip Stem**	**Procotyl P Acetabular Cup**	**Procotyl P Dual Mobility Cup**	**Wrist Joint Prosthesis System**	**3D-Printed Joints** 	**Shoulder Arthroplasty Product**
CRM	**LBBOT** (Assistance Lead Placement) CE 	**FLEXIGO - LBBAP delivery kit** CE & NMPA 	**LINEA - LBBAP Lead** CE & NMPA 	**Tilen & Eylen BLE MRI ICDs** 	**INVICTA Tachy lead** 	**ALIZEA BLE MRI pacemaker** 	**Leadless Pacemaker** CE & NMPA
Endo-vascular	**Aegis® II Abdominal Aortic Stent Graft System**		**Hector® Multi-branched Aortic Stent-Graft System**	**Below-the-Knee (BTK) Drug-Coated Balloon Dilation Catheter**	**Detachable Fibered Embolization Coil**	**Mechanical Thrombectomy Catheter**	**Thrombus Protection Device**
Neuro-vascular	**NuFairy™ Absorbable Coil Embolization System**	**Bridge® Vertebral Artery Bridge-MAX**	**Rebridge® Intracranial Visualized Stent**	**Intracranial Drug-Coated Balloon Catheter System**	**Intracranial Autodistensible Drug Stent**	**Intracranial Bulbar Expansion Drug Stent**	**Self-Expanding Drug-Eluting Stent**
Structural Heart	**VitaFlow® Liberty® Pro** 	**VitaFlow® AR**	**AnchorMan® Pro LAAC & LAAA System** 	**VitaFlow® SELFValve™**	**VitaFlow® Triumph™**	**AltaValve™ - Partnership with 4C Medical** 	
Surgical Robot	**Toumai® Remote Laparoscopic Surgical Robot** Upcoming overseas approvals 	**Toumai® Multiport Laparoscopic Surgical Robot** Upcoming overseas approvals	**SkyWalker™ Orthopedic Surgical Robot** Upcoming overseas approvals 	**Trans-bronchial Surgical Robot** 			
Electro-physiology[1]	**Pressure-Sensing Magnetically Guided Irrigated Pulsed-Field Ablation Catheter**		**Dual-Curve Pressure-Sensing Magnetic Radiofrequency Ablation Catheter**	**Mesh High-Density Mapping Catheter**	**Renal RF Ablation System**	**Flashpoint® Renal Artery Ablation Catheter**	**Ultrasound Imaging System**

Note: 1. Electrophysiology business is an associated company. 2. refers to NMPA approval unless otherwise specified.

Consolidated Income Statement

USD'000	2025 1H	2024 1H	Var.
Revenue	547,532	558,702	-2.0%
Cost of sales	(238,956)	(228,122)	4.7%
Gross profit	**308,576**	**330,580**	**-6.7%**
Research and development costs	(72,078)	(115,033)	-37.3%
Distribution costs	(148,551)	(156,150)	-4.9%
Administrative expenses	(82,785)	(83,785)	-1.2%
Other net income	54,785	12,390	342.2%
Other operating costs	(3,949)	(5,787)	-31.8%
Finance costs	(58,958)	(48,416)	21.8%
Changes in the fair value of convertible bonds	(12,399)	(15,108)	-17.9%
Changes in the fair value of other financial instruments	2,774	2,650	4.7%
Impairment losses of non-current assets	(23,361)	(6,561)	256.1%
Gain on disposal of subsidiaries and interests in equity-accounted investees	26,053	6,922	276.4%
Share of profits less losses of equity-accounted investees	(9,557)	(8,146)	17.3%
Loss before taxation	**(19,450)**	**(86,444)**	**-77.5%**
Income tax	(16,911)	(20,230)	-16.4%
Loss for the period	**(36,361)**	**(106,674)**	**-65.9%**
Attributable to: Equity shareholders of the Company	**(46,602)**	**(96,380)**	**-51.6%**

Consolidated Balance Sheet

USD'000	30 June 2025	31 Dec 2024	Var.
Non-current assets			
Investment properties	4,176	4,214	-1%
Property, plant and equipment	916,420	934,159	-2%
Intangible assets	229,100	234,317	-2%
Goodwill	201,100	188,514	7%
Equity-accounted investees	402,029	382,861	5%
Financial assets measured at fair value through profit or loss ("FVPL")	9,964	9,883	1%
Deferred tax assets	21,341	18,488	15%
Other non-current assets	118,011	123,713	-5%
Total non-current assets	**1,902,141**	**1,896,149**	**0%**
Current assets			
Financial assets measured at FVPL	115,565	51,817	123%
Inventories	352,020	379,288	-7%
Trade and other receivables	481,493	376,564	28%
Pledged deposits and time deposits	155,925	213,509	-27%
Cash and cash equivalents	764,498	712,995	7%
Assets classified as held-for-sale	3,290	3,100	6%
Total current assets	**1,872,791**	**1,737,273**	**8%**
Current liabilities			
Trade and other payables	651,874	638,997	2%
Contract liabilities	18,356	19,863	-8%
Interest-bearing borrowings	419,357	318,066	32%
Convertible bonds	161,131	147,133	10%
Lease liabilities	36,844	40,143	-8%
Income tax payable	27,488	7,311	276%
Derivative financial liabilities	7,547	7,500	1%
Total current liabilities	**1,322,597**	**1,179,013**	**12%**
Net current assets	**550,194**	**558,260**	**-1%**

Consolidated Balance Sheet (cont'd)

USD'000	30 June 2025	31 Dec 2024	Var.
Non-current liablities			
Interest-bearing borrowings	722,294	757,711	-5%
Lease liabilities	38,282	47,932	-20%
Deferred income	53,735	51,491	4%
Contract liabilities	31,227	26,948	16%
Convertible bonds	380,073	374,224	2%
Other payables	19,357	24,124	-20%
Derivative financial instruments	1,904	5,534	-66%
Deferred tax liabilities	24,099	21,601	12%
Total non-current liablities	**1,270,971**	**1,309,565**	**-3%**
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	623,100	603,455	3%
Total equity attributable to equity shareholders of the Company	**623,118**	**603,473**	**3%**
Non-controlling interests	558,246	541,371	3%
Total equity	**1,181,364**	**1,144,844**	**3%**

Eyes for greatness
Hands on details

MicroPort®